Table 6.

Identification of Prognostic Factors for Emergence of PA/I38T/M-Substituted Viruses by Logistic Regression Analysis

Parameter	Odds Ratio	95% CI	P Value
Sex (male to female)	0.474	.122–1.838	.2804
Baseline body weight (by 1 kg)	0.970	.899–1.046	.4299
Baseline sum of symptom scores (by 1 score)	0.765	.405–1.445	.4095
Baseline body temperature (by 1°C)	0.927	.323–2.662	.8886
Baseline virus-specific HAI antibody titer (≥40 to <40)	0.276	.078–0.982	.0467
Baseline influenza virus titer (by 1.0 log10TCID50/mL)	0.917	.589–1.429	.7017
Time to treatment from influenza onset (by 12 hours)a	0.428	.145–1.265	.1249
Meal before administration on day of dosing (yes to no)	1.109	.276–4.450	.8838

Patients with A(H3N2) virus who had paired-sequencing data available and had baseline characteristic data for potential risk factor were included in this analysis (N = 67). Abbreviations: CI, confidence interval; HAI, hemaggulutinin inhibition; PA/I38T, isoleucine substituted by threonine at position 38 of virus polymerase acidic protein; PA/I38M, isoleucine substituted by methionine at position 38 of virus polymerase acidic protein; TCID₅₀, 50% tissue culture infective dose.

^aTreated as ordered category of 4 levels.